<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464552</url>
  </required_header>
  <id_info>
    <org_study_id>N-2aa6-2018</org_study_id>
    <nct_id>NCT03464552</nct_id>
  </id_info>
  <brief_title>Celecoxib in Colposcopic Directed Biopsy</brief_title>
  <official_title>Role of Oral Celecoxib 200 mg in Reducing Pain Associated With Colposcopic Directed Biopsy: A Randomized Triple-blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women often experience pain and discomfort during colposcopic examination especially at time
      of colposcopic directed excisional biopsy, pre-procedure anxiety, women pain threshold may
      also increase pain, woman's cooperation during the procedure is affected by all these
      factors, which also may hinder the colposcopist from obtaining adequate data and biopsies.

      Several pharmacological and non-pharmacological methods have been studied to reduce pain
      associated colposcopic directed biopsy (CDB). We aim to study the effect of Celecoxib to
      reduce pain associated with CDB.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain during the procedure</measure>
    <time_frame>Immediately after the first biopsy</time_frame>
    <description>Visual analog score in mm on a 10 cm ruler</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at time of vaginal speculum application</measure>
    <time_frame>At time of introduction of vaginal speculum</time_frame>
    <description>Visual analog score in mm on a 10 cm ruler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure pain</measure>
    <time_frame>At 30 minutes after completing the procedure</time_frame>
    <description>Visual analog score in mm on a 10 cm ruler</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of pain score on duration of the colposcopic procure</measure>
    <time_frame>At time of removal of vaginal speculum</time_frame>
    <description>Duration in minutes (from introduction of vaginal speculum till its removal)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Colposcopy</condition>
  <arm_group>
    <arm_group_label>Celecoxib group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will receive oral placebo capsule once 3 hours before the colposcopic guided biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib 200mg</intervention_name>
    <description>oral capsule 3 hours before procedure</description>
    <arm_group_label>Celecoxib group</arm_group_label>
    <other_name>celebrex 200</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colposcopic guided biopsy</intervention_name>
    <description>Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.</description>
    <arm_group_label>Celecoxib group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>oral capsule 3 hours before procedure</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Females 18-65 years old who undergoing colposcopic directed biopsy

        Exclusion Criteria:

          -  A known allergy to Celecoxib, aspirin or another NSAID.

          -  Active peptic ulceration or gastrointestinal bleeding.

          -  Inflammatory bowel disease.

          -  Congestive heart failure (NYHA II-IV).

          -  Established ischemic heart disease, peripheral arterial disease and/or cerebrovascular
             disease.

          -  History of neurologic deficit.

          -  Known hepatic or renal impairment.

          -  Pregnancy.

          -  Breast-feeding.

          -  Post-hysterectomy.

          -  Bleeding disorders.

          -  Drug abuse.

          -  Cervical and vaginal infection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed AA Wali, MD</last_name>
    <phone>01001735088</phone>
    <phone_ext>+2</phone_ext>
    <email>ahmed.wali@kasralainy.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed AA Wali, MD</last_name>
      <phone>01001735088</phone>
      <phone_ext>+2</phone_ext>
      <email>ahmed.wali@kasralainy.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Ahmed AA Wali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed AA Wali, MD</investigator_full_name>
    <investigator_title>Lecturer of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>colposcopy - colposcopic directed biopsy - celecoxib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

